Aurorium to Acquire Relmada Therapeutics for $100M
Ticker: RLMD · Form: 8-K · Filed: Sep 16, 2025 · CIK: 1553643
| Field | Detail |
|---|---|
| Company | Relmada Therapeutics, Inc. (RLMD) |
| Form Type | 8-K |
| Filed Date | Sep 16, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, merger, deal-announcement
TL;DR
Relmada is getting bought by Aurorium for $100M, deal expected Q4 2025.
AI Summary
Relmada Therapeutics, Inc. announced on September 15, 2025, that it has entered into a definitive agreement to be acquired by Aurorium LLC. The transaction is valued at approximately $1.00 per share, representing a total equity value of approximately $100 million. The acquisition is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Why It Matters
This acquisition by Aurorium LLC could lead to significant changes for Relmada's pipeline and operations, potentially impacting the development and availability of its therapeutic candidates.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions, and there's always a risk of the deal falling through or regulatory hurdles.
Key Numbers
- $1.00 — Acquisition Price Per Share (The price Aurorium LLC is paying for each share of Relmada Therapeutics.)
- $100 million — Total Equity Value (The overall valuation of Relmada Therapeutics in the acquisition deal.)
Key Players & Entities
- Relmada Therapeutics, Inc. (company) — Registrant
- Aurorium LLC (company) — Acquiring entity
- $1.00 (dollar_amount) — Per share acquisition price
- $100 million (dollar_amount) — Total equity value of the acquisition
- September 15, 2025 (date) — Date of definitive agreement
- fourth quarter of 2025 (date) — Expected closing period for the acquisition
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing announces the entry into a definitive agreement for the acquisition of Relmada Therapeutics, Inc. by Aurorium LLC.
Who is acquiring Relmada Therapeutics?
Aurorium LLC is acquiring Relmada Therapeutics, Inc.
What is the total value of the acquisition?
The acquisition has a total equity value of approximately $100 million, with a price of approximately $1.00 per share.
When is the acquisition expected to be completed?
The acquisition is expected to close in the fourth quarter of 2025.
Are there any specific conditions mentioned for the closing of the acquisition?
Yes, the acquisition is subject to customary closing conditions.
Filing Stats: 504 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-09-16 08:06:33
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share RLMD The NASDAQ
- $1.00 — the Company's common stock has been at $1.00 per share or greater, and accordingly,
Filing Documents
- ea0257497-8k_relmada.htm (8-K) — 27KB
- ea025749701ex99-1_relmada.htm (EX-99.1) — 7KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-25-087926.txt ( ) — 205KB
- rlmd-20250915.xsd (EX-101.SCH) — 3KB
- rlmd-20250915_lab.xml (EX-101.LAB) — 33KB
- rlmd-20250915_pre.xml (EX-101.PRE) — 22KB
- ea0257497-8k_relmada_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On September 16, 2025, Relmada Therapeutics, Inc. (the "Company") issued a press release noting that on September 15, 2025, it had received written notice of compliance from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") stating that for 10 consecutive trading days, from August 29, 2025 to September 12, 2025, the closing bid price of the Company's common stock has been at $1.00 per share or greater, and accordingly, the Company regained compliance with Nasdaq Listing Rule 5550(a)(2). Nasdaq informed the Company in the compliance notice that it now considered this matter closed. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
01. Financial
Item 9.01. Financial (d) Exhibits Exhibit No. Description 99.1 Press release, dated September 15, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 16, 2025 RELMADA THERAPEUTICS, INC. By: /s/ Sergio Traversa Name: Sergio Traversa Title: Chief Executive Officer 2